Xilio Therapeutics Says Repayment In Q1 2024 Of Outstanding Loan Balance Under Xilio's Loan And Security Agreement With Pacific Western Bank, Will Be Sufficient To Fund Its Operating Expenses And Capital Expenditure Requirements Into Q2 2025.

4/1/24 4:31:05 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $XLO alert in real time by email

Get the next $XLO alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$XLO

Date	Price Target	Rating	Analyst
12/21/2022	$7.00	Buy	Chardan Capital Markets
1/10/2022	$36.00	Buy	HC Wainwright & Co.
11/16/2021	$40.00	Buy	Guggenheim
11/16/2021	$31.00	Outperform	Raymond James
11/16/2021		Outperform	Cowen & Co.
11/16/2021	$32.00	Overweight	Morgan Stanley

More analyst ratings

Xilio Therapeutics Announces Initial Clinical Trial Data from Phase 1C Dose Escalation for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Advanced Solid Tumors
Combination of vilastobart and atezolizumab demonstrated encouraging early evidence of anti-tumor activity, including unconfirmed partial responses observed in two patients with difficult-to-treat, immunologically "cold" tumors Complete resolution of a metastatic liver lesion observed in a patient with microsatellite stable colorectal cancer (MSS CRC) Safety data indicated combination of vilastobart and atezolizumab was generally well-tolerated and support the potential of vilastobart to be a differentiated next-generation anti-CTLA-4 in combination with PD-(L)1 inhibitors Continue to anticipate initial data from Phase 2 trial for combination of vilastobart and atezolizumab in metastatic
11/7/24 9:15:00 AM ET
$XLO
Biotechnology: Pharmaceutical Preparations
Health Care
Xilio Announces Initial Monotherapy Safety and Anti-Tumor Activity Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, in Late Line Patients with Advanced Solid Tumors
Initial evidence of dose-dependent disease control rate with 50% disease control rate at higher doses (≥2.8 mg/kg) and 31% disease control rate across all dose levels in a range of solid tumor types, including cold tumors Treatment-related adverse events primarily Grade 1-2 at doses up to 4 mg/kg administered once every three weeks in outpatient setting, with no reported signs or symptoms of vascular leak syndrome Two patients continuing treatment for more than 1 year, demonstrating XTX202 was well-tolerated with repeated, long-term dosing Plan to evaluate XTX202 as a monotherapy in ongoing Phase 2 proof-of-concept trial at 4.0 mg/kg in patients with advanced melanoma and renal cell carci
11/3/23 12:00:00 PM ET
$XLO
Biotechnology: Pharmaceutical Preparations
Health Care
Xilio to Host Virtual Investor Conference Call and Webcast on Monday, November 6, 2023 to Review Progress Across Pipeline, Including Phase 1/2 Clinical Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, Presented at the SITC Annual Meeting
WALTHAM, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that it will host an investor conference call and webcast on November 6, 2023 at 8:00 a.m. ET to review progress across its pipeline of tumor-activated molecules, including Phase 1/2 clinical data for XTX202, an investigational tumor-activated, engineered, beta-gamma IL-2, which will be presented at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, taking place in San Diego, California from November 1-5, 2023. The call will feature
10/31/23 9:15:00 AM ET
$XLO
Biotechnology: Pharmaceutical Preparations
Health Care

$XLO
Press Releases

Fastest customizable press release news feed in the world

Xilio Therapeutics Announces Initial Clinical Trial Data from Phase 1C Dose Escalation for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Advanced Solid Tumors
Combination of vilastobart and atezolizumab demonstrated encouraging early evidence of anti-tumor activity, including unconfirmed partial responses observed in two patients with difficult-to-treat, immunologically "cold" tumors Complete resolution of a metastatic liver lesion observed in a patient with microsatellite stable colorectal cancer (MSS CRC) Safety data indicated combination of vilastobart and atezolizumab was generally well-tolerated and support the potential of vilastobart to be a differentiated next-generation anti-CTLA-4 in combination with PD-(L)1 inhibitors Continue to anticipate initial data from Phase 2 trial for combination of vilastobart and atezolizumab in metastatic
11/7/24 9:15:00 AM ET
$XLO
Biotechnology: Pharmaceutical Preparations
Health Care
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial Results
Will present initial Phase 1C dose escalation data for vilastobart (XTX101), a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab, in a late-breaker poster presentation at the SITC Annual Meeting Expect to report initial Phase 2 data in microsatellite stable colorectal cancer (MSS CRC) for vilastobart in combination with atezolizumab in the fourth quarter of 2024 Expect to report Phase 1 data for XTX301, a tumor-activated IL-12, in the fourth quarter of 2024 WALTHAM, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people
11/7/24 9:05:00 AM ET
$XLO
Biotechnology: Pharmaceutical Preparations
Health Care
Xilio Therapeutics to Present Initial Phase 1C Dose Escalation Data for XTX101 (Vilastobart) in Combination with Atezolizumab in a Late-Breaker Poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
WALTHAM, Mass., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that initial data from its Phase 1C dose escalation of XTX101 (vilastobart) in combination with atezolizumab in patients with advanced solid tumors will be presented in a late-breaker poster session at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting taking place in Houston, Texas, from November 6-10, 2024. Poster presentation details: Title: Phase 1/2 Study of Vilastobart (formerly XTX101), a Tumor-Activated, Fc-enhanced Anti-CTL
10/30/24 9:01:00 AM ET
$XLO
Biotechnology: Pharmaceutical Preparations
Health Care

Xilio Therapeutics Appoints Aoife Brennan, M.D., and James Shannon, M.D., to its Board of Directors
WALTHAM, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced the appointment of Aoife Brennan, M.D., and James Shannon, M.D., to the company's board of directors. "On behalf of the entire board of directors, it is a privilege to welcome Aoife and James, both well-recognized biotech industry veterans, to the board of directors," said Paul Clancy, chair of the board of directors of Xilio Therapeutics. "Their extensive experience spanning all stages of drug development will be invaluable as Xilio progresses its
6/13/24 4:05:00 PM ET
$XLO
Biotechnology: Pharmaceutical Preparations
Health Care
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2022 Financial Results
XTX202, a tumor-activated IL‑2, successfully reached target dose range of 1 mg/kg in ongoing Phase 1 clinical trial; preliminary evidence of increased CD8+ effector T cells and NK cells observed with no signs of vascular leak syndrome XTX301, a tumor-activated IL-12, received FDA clearance for IND application; anticipate initiating patient dosing in Phase 1 clinical trial in first quarter of 2023 Plan to focus resources on advancing clinical-stage cytokine programs and will seek to partner XTX101, a tumor-activated anti-CTLA-4, to advance beyond ongoing Phase 1 monotherapy cohorts $139.1 million in cash and cash equivalents as of September 30, 2022, with anticipate
11/9/22 7:30:00 AM ET
$XLO
Biotechnology: Pharmaceutical Preparations
Health Care
Xilio Therapeutics Appoints Tomas J. Heyman to Board of Directors
WALTHAM, Mass., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today announced the appointment of Tomas J. Heyman to the company's board of directors. Mr. Heyman is a biopharmaceutical veteran with nearly 40 years of leadership and management expertise in corporate strategy, business development and venture capital from his tenure with Johnson & Johnson (J&J). In addition, the company announced that John Maraganore, Ph.D., former founding CEO of Alnylam Pharmaceuticals, will serve as a strategic advisor to Xilio's board of directors and its executive team.
9/15/22 4:05:00 PM ET
$XLO
Biotechnology: Pharmaceutical Preparations
Health Care

Xilio Therapeutics Says Repayment In Q1 2024 Of Outstanding Loan Balance Under Xilio's Loan And Security Agreement With Pacific Western Bank, Will Be Sufficient To Fund Its Operating Expenses And Capital Expenditure Requirements Into Q2 2025.

Chat with this insight

Recent Analyst Ratings for $XLO

$XLO Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Chardan Capital Markets initiated coverage on Xilio Therapeutics with a new price target

HC Wainwright & Co. initiated coverage on Xilio Therapeutics with a new price target

Guggenheim initiated coverage on Xilio Therapeutics with a new price target

$XLO Market Insights

Live Market Insights

Xilio Therapeutics' Q1 Cash And Cash Equivalents Of $34M, $30M Upfront Payment Received In April 2024 Under Gilead Agreement And Approximately $14.6M In Gross Proceeds From Private Placement In April 2024 Are Expected To Provide Cash Runway Into Q2 2025

Xilio Therapeutics Q1 2024 GAAP EPS $(0.62) Compared To $(0.83) A Year Ago

Xilio Therapeutics Currently May Offer And Sell Shares Of Co's Common Stock Having An Aggregate Offering Price Of Up To $18.7M

$XLO Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by SVP, FINANCE AND ACCOUNTING Brennan Kevin M.

New insider Chudnovsky Yekaterina claimed ownership of 7,000,000 shares (SEC Form 3)

SEC Form 4 filed by Chief Operating Officer Frankenfield Christopher James

$XLO Financials

Live finance-specific insights

Xilio Therapeutics Announces Initial Clinical Trial Data from Phase 1C Dose Escalation for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Advanced Solid Tumors

Xilio Announces Initial Monotherapy Safety and Anti-Tumor Activity Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, in Late Line Patients with Advanced Solid Tumors

Xilio to Host Virtual Investor Conference Call and Webcast on Monday, November 6, 2023 to Review Progress Across Pipeline, Including Phase 1/2 Clinical Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, Presented at the SITC Annual Meeting

$XLO Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Xilio Therapeutics Inc.

Amendment: SEC Form SC 13G/A filed by Xilio Therapeutics Inc.

Amendment: SEC Form SC 13G/A filed by Xilio Therapeutics Inc.

$XLO Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Gilead Sciences, Inc. bought $368,790 worth of shares (485,250 units at $0.76), increasing direct ownership by 7% to 7,345,473 units (SEC Form 4)

$XLO Press Releases

Fastest customizable press release news feed in the world

Xilio Therapeutics Announces Initial Clinical Trial Data from Phase 1C Dose Escalation for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Advanced Solid Tumors

Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial Results

Xilio Therapeutics to Present Initial Phase 1C Dose Escalation Data for XTX101 (Vilastobart) in Combination with Atezolizumab in a Late-Breaker Poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

$XLO Leadership Updates

Live Leadership Updates

Xilio Therapeutics Appoints Aoife Brennan, M.D., and James Shannon, M.D., to its Board of Directors

Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2022 Financial Results

Xilio Therapeutics Appoints Tomas J. Heyman to Board of Directors

$XLO SEC Filings

SEC Form 10-Q filed by Xilio Therapeutics Inc.

Xilio Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

Xilio Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Recent Analyst Ratings for
$XLO

$XLO
Analyst Ratings

$XLO
Market Insights

$XLO
Insider Trading

$XLO
Financials

$XLO
Large Ownership Changes

$XLO
Insider Purchases

$XLO
Press Releases

$XLO
Leadership Updates

$XLO
SEC Filings